New drug trial aims to guard Kids' transplants from Leukemia's return
NCT ID NCT07498465
Summary
This early-stage trial is testing a drug called revumenib as a 'maintenance therapy' for children and young adults with certain types of leukemia. The goal is to see if taking the drug for up to a year after a stem cell transplant is safe, find the right dose, and see if it helps prevent the cancer from coming back. The study will enroll up to 29 participants under 22 years old who have recently had a transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.